ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-Term Efficacy and Safety of Elobixibat for Chronic Constipation Assessed by Rectal Ultrasonography: A Retrospective Observational Study.Diagnostics (Basel, Switzerland) · 2026Article
- Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bowel stool and/or gas distribution is an important indicator of bowel function. The mean colonic transverse diameter of the colon and rectum (constipation index) is a stool and/or gas distribution parameter assessed via transabdominal ultrasonography and an indirect indicator of colonic transit time. Elobixibat, an ileal bile acid transporter inhibitor, increases the number of bowel movements in chronic constipation (CC) patients. Aims: To determine whether the constipation index changes following treatment with elobixibat and evaluate the relationship between changes in the constipation index and fecal bile acid concentration. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled trial in 17 CC patients aged ≥ 60 years who were administered elobixibat or placebo daily for 1 week. Changes in stool and/or gas distribution and stool bile acid concentrations were analyzed before and after treatment. Results: Elobixibat, but not placebo, significantly reduced the constipation index. A significant negative correlation was found between the change in the constipation index and the change in total fecal bile acid concentration. Conclusion: Elobixibat increases the total fecal bile acid concentration of CC patients, which results in shortened colonic transit time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.